Recombinant bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy: current strategies

被引：8

作者：

Wang, Yonghua ^{[1
]}

Yang, Meng ^{[1
]}

Yu, Qinchao ^{[1
]}

Yu, Lun ^{[1
]}

Shao, Shixiu ^{[1
]}

Wang, Xinsheng ^{[1
]}

机构：

[1] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266071, Peoples R China

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 01期

基金：

中国国家自然科学基金;

关键词：

bacillus Calmette-Guerin; BCG; immunotherapy; intravesical therapy; recombinant BCG; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; EXPRESSING PERTUSSIS TOXIN; GAMMA-INDUCING FACTOR; MYCOBACTERIUM-BOVIS; IFN-GAMMA; INTRAVESICAL THERAPY; DNA VACCINES; MITOMYCIN-C; TH1-STIMULATING CYTOKINES; PLUS INTERFERON-ALPHA-2B;

D O I：

10.1586/14737140.2015.961430

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bacillus Calmette-Guerin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have focused on recombinant BCG (rBCG) which provides a novel tactic for modification of BCG. To date, a number of rBCG strains have been developed and demonstrated to encourage efficacy and safety in preclinical and clinical studies. This review summarizes current rBCG strategies, concerns and future directions in UBC immunotherapy with an intention to encourage further research and eventually to inform clinical decisions.

引用

页码：85 / 93

页数：9

共 97 条

[1] Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer [J].

Ahirwar, Dinesh ;

Kesarwani, Pravin ;

Manchanda, Parmeet Kaur ;

Mandhani, Anil ;

Mittal, Rama Devi .

CANCER GENETICS AND CYTOGENETICS, 2008, 184 (01) :1-8

[2]

Ahn HJ, 1997, J IMMUNOL, V159, P2125

[3]

Alexandroff AB, 2010, IMMUNOTHERAPY-UK, V2, P551, DOI [10.2217/imt.10.32, 10.2217/IMT.10.32]

[4] The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer [J].

Andrade, Priscila M. ;

Chade, Daher C. ;

Borra, Ricardo C. ;

Nascimento, Ivan P. ;

Villanova, Fabiola E. ;

Leite, Luciana C. C. ;

Andrade, Enrico ;

Srougi, Miguel .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (05) :520-525

[5]

[Anonymous], ADV UROL

[6] Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-γ [J].

Arnold, J ;

de Boer, EC ;

O'Donnell, MA ;

Böhle, A ;

Brandau, S .

JOURNAL OF IMMUNOTHERAPY, 2004, 27 (02) :116-123

[7] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013 [J].

Babjuk, Marko ;

Burger, Maximilian ;

Zigeuner, Richard ;

Shariat, Shahrokh F. ;

van Rhijn, Bas W. G. ;

Comperat, Eva ;

Sylvester, Richard J. ;

Kaasinen, Eero ;

Boehle, Andreas ;

Palou Redorta, Joan ;

Roupret, Morgan .

EUROPEAN UROLOGY, 2013, 64 (04) :639-653

[8] Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy [J].

Basturk, Bilkay ;

Yavascaoglu, Ismet ;

Oral, Barbaros ;

Goral, Guher ;

Oktay, B. .

CYTOKINE, 2006, 35 (1-2) :1-5

[9] Co-administration of intravesical bacillus Calmette-Guerin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder [J].

Bazarbashi, Shouki ;

Soudy, Hussein ;

Abdelsalam, Mahmoud ;

Al-Jubran, Ali ;

Akhtar, Saad ;

Memon, Muhammad ;

Aslam, Muhammad ;

Kattan, Said ;

Shoukri, Mohamed .

BJU INTERNATIONAL, 2011, 108 (07) :1115-1118

[10] INTERNALIZATION OF BACILLE CALMETTE-GUERIN BY BLADDER-TUMOR CELLS [J].

BECICH, MJ ;

CARROLL, S ;

RATLIFF, TL .

JOURNAL OF UROLOGY, 1991, 145 (06) :1316-1324

← 1 2 3 4 5 6 7 8 9 10 →